Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00639509 · ClinicalTrials.gov registry record · Phase 2
IMC-A12 in Treating Patients With Advanced Liver Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00639509: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00639509 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00639509, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This phase II trial is studying how well IMC-A12 works in treating patients with advanced liver cancer. Monoclonal antibodies, such as IMC-A12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Interventions
- PROCEDURE computed tomography
- PROCEDURE contrast-enhanced magnetic resonance imaging
- BIOLOGICAL cixutumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00639509
The ClinicalTrials.gov registry entry for NCT00639509 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which computed tomography is the first listed.
NCT00639509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00639509 about?
NCT00639509 is a clinical study titled "IMC-A12 in Treating Patients With Advanced Liver Cancer". This phase II trial is studying how well IMC-A12 works in treating patients with advanced liver cancer. Monoclonal antibodies, such as IMC-A12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumo...
What is the current status of trial NCT00639509?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-03. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00639509?
The interventions under investigation include: computed tomography (PROCEDURE), contrast-enhanced magnetic resonance imaging (PROCEDURE), cixutumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00639509?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.